Nimotop (Nimodipine)

Nimodipine acts on cerebral vascular smooth muscle to prevent vasospasm after subarachnoid hemorrhage.

• Subarachnoid hemorrhage: prevention of delayed cerebral vasospasm.
• Aneurysmal subarachnoid hemorrhage: reduction of secondary ischemic injury.
• Neurovascular protection: supports cerebral blood flow after hemorrhagic events.

• Nimodipine selectively blocks L‑type calcium channels on cerebral arterial smooth muscle, decreasing calcium influx. This preferential vasodilation of cerebral vessels lowers vascular resistance, mitigates vasospasm, and improves perfusion to ischemic brain tissue after subarachnoid hemorrhage.

Nimotop may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain, often transient.
• Hypotension: low blood pressure that can cause light‑headedness.
• Nausea: feeling of stomach upset.
• Flushing: warm sensation and reddening of the skin.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure requiring medical attention.
• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.
• Hepatic injury: elevated liver enzymes or jaundice.
• Anaphylactic reaction: severe allergy with breathing difficulty.

Before initiating therapy, clinicians should consider several safety measures.

• Monitor blood pressure: check regularly for hypotension.
• Assess liver function: perform baseline and periodic liver enzyme tests.
• Use caution in cardiac disease: avoid in patients with severe heart failure or conduction disorders.
• Avoid concurrent potent vasodilators: limit use with other calcium channel blockers or nitrates.
• Adjust in renal impairment: consider dose modification in severe renal dysfunction.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nimodipine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma concentrations, raising toxicity risk.
• Nitrates or other vasodilators: combined use can lead to profound blood pressure drops.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower nimodipine levels and reduce efficacy.
• Antihypertensive agents (e.g., ACE inhibitors, ARBs): may enhance blood pressure lowering.
• Beta‑blockers: can potentiate bradycardia when combined with nimodipine.